DataMeds AI, Inc. (Nasdaq: WGRX) adopts MEDS ticker in AI shift
Rhea-AI Filing Summary
Wellgistics Health, Inc. has amended its Delaware charter to change its corporate name to DataMeds AI, Inc., effective July 22, 2026. On the same date, its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol MEDS, replacing WGRX.
The company states that the name and symbol changes do not alter stockholder rights or require any stockholder action. Management frames the rebranding around an AI-driven digital health strategy integrating its EinsteinRx and PharmacyChain platforms with the Health Lives Here app and other telemedicine and data-management offerings.
Positive
- None.
Negative
- None.
Filing Explained
The filing's legal status is more precise than the exhibit's headline: the charter amendment was filed on July 20, but the name change becomes effective on July 22, when trading under MEDS is scheduled to begin. As of the July 21 filing, the change was therefore not yet effective.
8-K Event Classification
Key Figures
Key Terms
Certificate of Amendment regulatory
General Corporation Law of the State of Delaware regulatory
Nasdaq Capital Market financial
blockchain technical
telemedicine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What corporate name change did WGRX announce in July 2026?
When will WGRX change its Nasdaq ticker and what is the new symbol?
Does the WGRX name and ticker change affect stockholder rights or require action?
What business focus does DataMeds AI, Inc. (WGRX) describe after rebranding?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On July 20, 2026, Wellgistics Health, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware to change the name of the Company to “DataMeds AI, Inc.” (the “Name Change”), effective July 22, 2026.
Pursuant to Section 242 of the General Corporation Law of the State of Delaware, no stockholder approval was required for the Charter Amendment because it only related to a name change. A copy of the Charter Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
In connection with the Name Change, the Company’s trading symbol for its common stock will begin trading on the Nasdaq Capital Market on July 22, 2026 as “MEDS” (the “Symbol Change”).
Neither the Name Change, nor the Symbol Change, affects the rights of the Company’s stockholders, and stockholders do not need to take any action in connection with the Name Change or the Symbol Change. The CUSIP number for the Company’s common stock remains 949503205.
Item 8.01. Other Events.
On July 21, 2026, the Company issued a press release announcing the Name Change and Symbol Change. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.
| Exhibit No. | Description of Exhibit | |
| 3.1 | Certificate of Amendment to Amended and Restated Certificate of Incorporation dated July 20, 2026 | |
| 99.1 | Press release dated July 21, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 21, 2026 | WELLGISTICS HEALTH, INC. | |
| By: | /s/ Prashant Patel | |
| Prashant Patel, President | ||
Exhibit 99.1
 |
PRESS RELEASE DATAMEDS AI, INC. 3000 BAYPORT DRIVE, SUITE 950 TAMPA, FLA. 33607 WEBSITE
RUBENSTEIN PUBLIC RELATIONS CONTACT: JAMES LAMBERT 212-805-3024 JLAMBERT@RUBENSTEINPR.COM |
FOR IMMEDIATE RELEASE
WELLGISTICS HEALTH, INC. OFFICIALLY CHANGES CORPORATE NAME TO DATAMEDS AI, INC.
Leading Health IT Company’s Rebranding Reflects Updated Healthcare Ecosystem Aligned with AI Integration to Optimize Patient Control of Healthcare Data
TAMPA, Fla. –Tuesday, July 21, 2026 - Wellgistics Health, Inc., (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced that it has officially completed its name change to DataMEDS AI, Inc. (“DataMEDS” or “the Company”). Simultaneous with this announcement, the Company announced that it will begin trading under the stock symbol ‘MEDS’ on the NASDAQ Capital Market stock exchange on Wednesday, July 22, 2026.
DataMeds aims to deliver a vertically aligned healthcare ecosystem to patients that expands EinsteinRx™’s technological capabilities into medical, laboratory and wearables fields through a proprietary blockchain, leveraging unique drug-adjunct products to tailor patient-specific solutions through the Health Lives Here app, initially targeting GLP-1-associated muscle loss and Long COVID patient bases. The Company intends to leverage Health Lives Here’s unique patient-engagement infrastructure to consolidate electronic health data into our proprietary health-centered blockchain infrastructure to enable patients to participate in data transaction revenue, reduce data friction for providers, and allow for tailored clinical trial offerings of both prescription drugs and/or proprietary nutraceutical products for patients seeking to reach specific health goals.
“Today’s announcement is the start of a new chapter in healthcare as we lay the groundwork for patients being able to seize control of their health data,” said Gerald Commissiong, Gerald E. Commissiong, Interim Co-CEO of Wellgistics Health. “From the pending launch of our digital platform under the consumer Health Lives Here app, to expanding EinsteinRx AI technology into new medical fields to help consolidate data access for patients, providers, pharmacists, pharmaceutical manufacturers and payors/PBMs, DataMeds AI is building a more cohesive digital health environment that allows for greater efficiency and better health outcomes by breaking down the data sharing barriers that exist in our healthcare system today.”
For more information about DataMeds AI, Inc. visit their website or contact James Lambert, Vice President at Rubenstein Public Relations, at jlambert@rubensteinpr.com or at 212-805-3024.
About DataMeds AI, Inc.
DataMeds AI, Inc., (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ into the Health Lives Here Mobile application and Tollo Health.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the proposed corporate name change to DataMeds AI, Inc.; the proposed rebranding of the Company’s Pharmacy and Pharmacy Services division as Corexa Health; the Company’s proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the anticipated timing, structure, terms and completion of such transaction; the satisfaction or waiver of closing conditions; the receipt of stockholder approval and any other required approvals; the Company’s anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the Company’s ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company’s technology platforms, strategic relationships and business combinations; the Company’s capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company’s ability to maintain compliance with Nasdaq listing standards; and the Company’s liquidity, capital resources and ability to fund operations.
Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the proposed name change may not be approved by stockholders or otherwise completed; the risk that the proposed transaction may not be completed on the anticipated terms or timeline, or at all; the risk that closing conditions may not be satisfied or waived; risks related to integrating multiple businesses, technologies and platforms; risks related to the development, commercialization, adoption, scalability and regulatory treatment of artificial intelligence, blockchain-enabled data management, telemedicine, pharmacy, laboratory, wearable-device and digital health technologies; risks related to healthcare privacy, cybersecurity, data ownership, data monetization and compliance with applicable healthcare, pharmacy, consumer protection, data protection and securities laws; risks related to the Company’s liquidity, capital resources, indebtedness, dilution, outstanding securities, registration statements and ability to raise additional capital; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory, competitive and operational risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence, technology and digital asset sectors; and other risks described in the Company’s filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Wellgistics Media Contact
James Lambert, Vice President
Rubenstein Public Relations
Phone: 212.805.3024
Email: jlambert@rubensteinpr.com
Wellgistics Investor Contact
Investor Relations: IR@wellgisticshealth.com
###